Diabetes, metabolic syndrome and obesity : targets and therapyOct 28, 2026

Pancreatic and Gallbladder Problems Linked to Tirzepatide Use for Obesity

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 29, 2026

Abstract

Tirzepatide is associated with significant weight reduction in individuals with obesity.

Obesity is linked to various comorbidities and increased healthcare costs.
Tirzepatide acts as a dual receptor agonist for GIP and GLP-1.
Uncertainty persists about the safety of tirzepatide concerning pancreatic and gallbladder health.
The safety profile may vary across different populations and evidence sources.

Simplified

Obesity is a chronic and relapsing condition that affects all demographics and results in comorbidities, rising healthcare costs, and social challenges. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising therapy offering significant weight reduction. However, uncertainty remains regarding its pancreatic and gallbladder safety profile across different populations and evidence sources.

Full Text

Full text is available at the source.

View Full Text ↗

Pancreatic and Gallbladder Problems Linked to Tirzepatide Use for Obesity

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief